| 2008 Update Speakers | | | « back to Update hompage | Wade Berrettini, M.D., Ph.D. | | Current and Future Genetic Testing for Psychiatry Disorders | | | | BIO | Dr. Berrettini is the Karl E. Rickels Professor of Psychiatry, at the University of Pennsylvania School of Medicine. He earned his MD (1977) degree and PhD (Pharmacology, 1979) from Thomas Jefferson University. After completing residency training in Psychiatry, he studied genetics of behavioral disorders at the National Institute of Mental Health. For the past decade, Dr. Berrettini has been the Director of the Center for Neurobiology and Behavior, a group of interdisciplinary scientists studying genetic and biologic influences on brain disorders and behavior. The author of more than 250 peer-reviewed scholarly publications, his research interests include genetics and pharmacogenetics of mood disorders, addictions, epilepsy and eating disorders. In addition to serving on the editorial boards of Neuropsychopharmacology, Molecular Psychiatry and the American Journal of Psychiatry, he has acted as a consultant to pharmaceutical companies, including GSK, J&J, Wyeth, Lilly, Novartis and Astra-Zeneca.
| | | | | OBJECTIVES | | At the completion of this session, the participant should be able to: | | | 1. Discuss the complex, multigenic nature of genetic susceptibility in bipolar disorder,
nicotine addiction and alcoholism.
2. Identify risk-increasing genes in each of these disorders.
3. Evaluate the potential for pharmacogenetics to improve outcomes. | |
| | | | | | | | | | | | | | | | | | | | |  |
|
